INTRODUCTION AND OBJECTIVES: Prostate-specific antigen (PSA) screening in men of average risk remains controversial. Results from PSA clinical trials are widely cited in patient education materials, but patients' ability to incorporate probability and risk data into their decision-making may depend on their numeracy, or facility with quantitative concepts. This study assessed men's numeracy and its impact on their understanding of the risk reduction benefits of PSA screening.
METHODS: Cross-sectional survey study. Men 40-75 years old attending a general medicine clinic were invited to complete a survey, which included demographics, personal PSA and prostate cancer (CaP) history, and a validated 3-item numeracy test. Numeracy was scored as the number of items correctly answered (range 0-3). Surveys also presented PSA risk reduction data derived from the European Randomized Study of Screening for Prostate Cancer, framed in 1 of 4 ways: absolute or relative risk reduction (ARR or RRR), with or without baseline risk (BR). Respondents were asked to adjust their perceived risk of CaP mortality using the risk data presented. Accuracy of risk reduction was evaluated relative to how risk data were framed.
RESULTS: 200 men completed the survey (60% response rate). Mean age was 60 years, 51% had received a PSA test, and 5% reported a CaP diagnosis. Respondents' demographics were not significantly different among the 4 survey formats. Most men incorrectly answered 1 or more of the 3 numeracy items; half could not convert "1 in 1000" to a percentage, and one-quarter could not calculate "1% of 1000." Overall accuracy of perceived risk adjustment based on PSA data was 20% among all groups. Accuracy varied with how data were framed: when presented with RRR, men were 13% accurate without BR and 31% accurate with BR; when presented with ARR, they were 0% accurate without BR and 35% accurate with BR. Including BR data significantly improved accuracy for both RRR (P¼0.03) and ARR groups (P<0.01). Accuracy was significantly related to numeracy; numeracy scores of 0, 1, 2, and 3 were associated with accuracy rates of 6%, 5%, 9%, and 36%, respectively (P<0.01). Neither PSA testing history nor CaP history was associated with accuracy.
CONCLUSIONS: Patients' numeracy was significantly associated with the accuracy of interpreting quantitative benefits of PSA screening. Although accuracy improved when the presentation of risk reduction data was framed by baseline risk, numeracy in this screening population of men was poor overall. Alternative methods of communicating concepts of risk to patients may facilitate shared decisionmaking. INTRODUCTION AND OBJECTIVES: Elevated glucose uptake and lactate production in the availability of oxygen, a phenomenon called the Warburg effect, is important for cancer cell growth. Phosphorylation of Pyruvate kinase isozyme M2 (PKM2) by ERK promotes its nuclear localization and the Warburg effect. O-class forkhead factor 1 (FOXO1) acts as a tumor suppressor in the nucleus. FOXO1 can be phosphorylated by activated AKT and exported to cytoplasm, thereby losing its tumor suppressor function. Here, we revealed that AKTphosphorylated FOXO1 inhibits IQGAP1-augmented activation of ERK. We also investigated whether AKT-phosphorylated FOXO1 inhibits PKM2 nuclear localization and Warburg effect in prostate cancer.
Source of Funding: None
METHODS: We used co-IP to determine protein interaction, Western-blot to detect the protein level, RT-PCR to detect gene expression level, immunocytochemistry to detect PKM2 cellular localization, immunohistochemistry to analysize FOXO1 and phosphor-ERK level in human prostate cancer using tissue microarray (TMA). Glucose or lactate levels were determined using a glucose assay kit or lactate assay kit. IQBP was a small phosphor-mimicking peptide derived from FOXO1. PC-3-Luc cells were injected into NSG mice to generate xenograft model. RESULTS: We identified the scaffold protein IQGAP1 as a binding partner of FOXO1 (Fig. a) . We demonstrated that activated AKT is important for FOXO1-IQGAP1 interaction (Fig. b and c) , and AKTphosphorylated FOXO1 at serine-319 is critical for FOXO1 binding to IQGAP1 (Fig. d) . Phosphorylated FOXO1 inhibits IQGAP1-augmented phosphorylation of ERK( Fig. e-g) . We also found that there is an inverse correlation between FOXO1 and phosphorylated ERK1/2 in human prostate cancer tissues ( Fig. h and i) . Phosphorylated FOXO1 (cytoplasmic) inhibits PKM2 nuclear localization (Fig. j) and knockdown of FOXO1 promotes PKM2 nuclear localization (Fig. k) . We further demonstrated that phosphorylated FOXO1 (cytoplasmic) inhibits Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1165 expression of PKM2 target gene and induces glucose uptake and lactate production ( Fig. l and m) . Finally, we demonstrated that IQBP overcomes docetaxel (DTX)-induced chemoresistance through inhibiting Warburg effect in vivo ( Fig. n and o) . CONCLUSIONS: AKT-phosphorylated FOXO1 inhibits PKM2 nuclear localization and Warburg effect in prostate cancer. 
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TUMOR-ASSOCIATED MACROPHAGES PROMOTE PROSTATE CANCER METASTASIS VIA CCL2-CCR2 AXIS-INDUCED CCL22-CCR4 AXIS Kouji Izumi*, Aerken Maolake, Ariunbold Natsagdorj, Kazutaka Narimoto, Yoshifumi Kadono, Atsushi Mizokami, Kanazawa, Japan INTRODUCTION AND OBJECTIVES: Early studies have found that tumor-associated macrophages (TAMs) promote cancer progression. We previously reported that TAMs promote prostate cancer metastasis via activation of the CCL2-CCR2 axis. Recently, it was reported that the CCR4 (receptor of CCL17 and CCL22) expression level in breast cancer was associated with lung metastasis. However, the role of CCR4 and the relationship between CCR2 and CCR4 in prostate cancer is unclear. The aim of this study was to elucidate the role of CCR4 and the relationship between CCL2-CCR2 axis and CCL17/ CCL22-CCR4 axis in prostate cancer progression.
METHODS: Human prostate cancer cell line cells and monocyte-lineage cells were used. Transwell migration and invasion assays co-cultured with or without macrophages were performed. Chemokines and their receptors in prostate cancer cells were measured. CCR2 and CCR4 in prostate cancer tissue were immunohistochemically analyzed. RESULTS: Co-culture of macrophages and prostate cancer cells increased prostate cancer cell migration and invasion and induced secretion of CCL2. CCL2 promoted prostate cancer cell migration in an autocrine manner and induced CCR2, CCR4 expressions, and CCL22 secretion of prostate cancer cells. RT-PCR, western blotting, and immunocytochemical staining revealed both CCR2 and CCR4 expressions in prostate cancer cells. CCL22 also promoted prostate cancer cell migration. Blockade of the CCL2-CCR2 or CCL17/22-CCR4 axis with receptor antagonist inhibited the migration of prostate cancer cells. The CCL2-CCR2 and CCL22-CCR4 axes increased phosphorylation of Akt and Erk1/2. Although both CCR2 and CCR4 antagonists could inhibit phosphorylation of Akt and Erk1/2, the CCR4 antagonist, compared with the CCR2 antagonist, strongly inhibited phosphorylation of Akt. CCR4 may have contributed more to prostate cancer cell migration than did CCR2. CCR4 and CCR2 were increased in prostate cancer tissues by IHC staining. Interestingly, the staining intensities of CCR2 and CCR4 in each specimen were significantly correlated. Moreover, the staining intensity of CCR4 was correlated with the progression of TNM stage.
CONCLUSIONS: This is the first study to show that CCR4 was expressed in prostate cancer cell lines and human prostate cancer tissues and that the CCL22-CCR4 axis contributed to prostate cancer migration and invasion. Targeting of the CCL22-CCR4 axis, which is activated by TAMs, may be a novel therapeutic target and a potential biomarker for prostate cancer.
INTRODUCTION AND OBJECTIVES: Novel strategies for candidate biomarker discovery in prostate cancer (PC) are needed to address the lack of specificity of prostate specific antigen (PSA) in PC screening and diagnosis. Urine is a very attractive biological fluid for prostate cancer biomarker discovery and measurement, since it is easy to obtain, non-invasive and may reflect biochemical processes within the prostate. Our aim is to search for proteins in the urine of patients with diagnosis of PC using isobaric labeling combined with high sensitive mass spectrometry-based proteomics.
METHODS: In this study we performed isobaric labeling combined with high sensitive and accurate mass spectrometry-based proteomics to identify proteins that are differentially expressed in the urine of men with PC comparing with those with benign prostate hyperplasia (BPH).
RESULTS: In total, 725 proteins were identified; amongst them 51 and 73 proteins were up and down regulated respectively in patients with PC. Two peptides from MMP-9 and Ly-6/neurotoxin-like were identified significantly up-regulated in PC and were further validated using a complementary targeted proteomic approach. Furthermore, we also quantified the expression of MMP9 in a set of 10 control and 17 prostate cancer urines, using ELISA, demonstrating that the expression of MMP9 is statistically higher in the urines from prostate cancer patients compared to controls (T-test, p<0.05). The activity of metalloproteinase was measured using zymography but no correlation between expression and activity in the urine samples from BPH and PC was observed.
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